| Style | Citing Format |
|---|---|
| MLA | Fs Hosseini Fatemeh SADAT, Z Sharifi ZAHRA, H Khalili HOSSEIN. "Is Including a Carbapenem in Treatment Regimens for Infections Caused by Multidrug-Resistant Gram-Negative Pathogens Still Reasonable?." American Journal of Therapeutics, vol. , no. , 2025, pp. -. |
| APA | Fs Hosseini Fatemeh SADAT, Z Sharifi ZAHRA, H Khalili HOSSEIN (2025). Is Including a Carbapenem in Treatment Regimens for Infections Caused by Multidrug-Resistant Gram-Negative Pathogens Still Reasonable?. American Journal of Therapeutics, (), -. |
| Chicago | Fs Hosseini Fatemeh SADAT, Z Sharifi ZAHRA, H Khalili HOSSEIN. "Is Including a Carbapenem in Treatment Regimens for Infections Caused by Multidrug-Resistant Gram-Negative Pathogens Still Reasonable?." American Journal of Therapeutics , no. (2025): -. |
| Harvard | Fs Hosseini Fatemeh SADAT, Z Sharifi ZAHRA, H Khalili HOSSEIN (2025) 'Is Including a Carbapenem in Treatment Regimens for Infections Caused by Multidrug-Resistant Gram-Negative Pathogens Still Reasonable?', American Journal of Therapeutics, (), pp. -. |
| Vancouver | Fs Hosseini Fatemeh SADAT, Z Sharifi ZAHRA, H Khalili HOSSEIN. Is Including a Carbapenem in Treatment Regimens for Infections Caused by Multidrug-Resistant Gram-Negative Pathogens Still Reasonable?. American Journal of Therapeutics. 2025;():-. |
| BibTex | @article{ author = {Fs Hosseini Fatemeh SADAT and Z Sharifi ZAHRA and H Khalili HOSSEIN}, title = {Is Including a Carbapenem in Treatment Regimens for Infections Caused by Multidrug-Resistant Gram-Negative Pathogens Still Reasonable?}, journal = {American Journal of Therapeutics}, volume = {}, number = {}, pages = {-}, year = {2025} } |
| RIS | TY - JOUR AU - Fs Hosseini Fatemeh SADAT AU - Z Sharifi ZAHRA AU - H Khalili HOSSEIN TI - Is Including a Carbapenem in Treatment Regimens for Infections Caused by Multidrug-Resistant Gram-Negative Pathogens Still Reasonable? JO - American Journal of Therapeutics VL - IS - SP - EP - PY - 2025 ER - |